WAYNE, PA — Teleflex Incorporated (NYSE: TFX), a noted player in the medical technology industry, recently announced its participation in the 2024 American Urological Association Annual Meeting in San Antonio, TX, from May 3-6. The company is set to present multiple clinical studies that spotlight the safety, efficacy, and patient satisfaction associated with the Prostatic Urethral Lift (PUL) using its UroLift™ System for treating benign prostatic hyperplasia (BPH).
At the forefront of these presentations are two notable randomized clinical trials (RCTs) comparing the UroLift™ System against other treatment modalities for BPH. These studies aim to provide a comprehensive look at the post-surgery outcomes, including medication use, hospitalization rates, and adverse events when compared to standard treatments for this prevalent condition.
Additionally, Teleflex will introduce the UroLift™ 2 System with Advanced Tissue Control (ATC) at the meeting. This innovation, which has already received FDA clearance, promises enhanced precision and ease for physicians performing the procedure. The ATC System features tissue control wings and laser-etched needle markers designed for accurate targeting and manipulation of obstructive prostate tissue. A more efficient delivery system aims to improve physician comfort and procedural efficiency.
Benign prostatic hyperplasia, or BPH, is a common condition affecting a significant portion of the male population as they age. It involves the enlargement of the prostate gland, leading to urinary discomfort and other symptoms due to the obstruction of the urethra. The UroLift™ System offers a minimally invasive solution aimed at alleviating these symptoms without the need for major surgery or the destruction of prostate tissue. It stands out as the only leading procedure for enlarged prostate that preserves sexual function and does not involve heating, cutting, or removal of prostate tissue.
Liam Kelly, Chairman, President, and CEO of Teleflex, emphasized the importance of rigorous clinical trials in determining the relative safety and effectiveness of different BPH treatments. He stated, “Assessing the comparative safety and effectiveness of leading therapeutic modalities through clinical trials is paramount in optimizing patient-centered care for benign prostatic hyperplasia.” Kelly further highlighted the company’s dedication to generating both clinical and real-world evidence to support the application of the UroLift™ procedure in enhancing patient outcomes.
Teleflex’s latest findings and the unveiling of the UroLift™ 2 System at the American Urological Association Annual Meeting signal a significant advancement in the treatment of BPH. By offering innovative solutions that focus on patient experience and outcomes, Teleflex continues to lead in the development of less invasive, effective treatments for common conditions affecting men’s health.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.